Sartorius stock rises 3.24 percent with P/ E 91.73

Published on 10/14/2026 at 17:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius stock costs EUR 259.45 on October 14, 2026, up 3.24 percent versus the Xetra close. The third-quarter report is due October 22, 2026.

Trading momentum and valuation

Sartorius stock stood 3.24 percent above the Xetra close on October 14, 2026.
Sartorius guides for 5 to 9 percent sales growth in fiscal 2026.
Sartorius stock costs EUR 259.45 at Lang & Schwarz on October 14, 2026 at 5:05 p.m. CEST, 3.24 percent above the Xetra close of October 13, 2026.
The price-to-earnings ratio was 91.73 on October 14, 2026.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius stock (ISIN DE0007165631) stood at EUR 259.45 at Lang & Schwarz on October 14, 2026 at 5:05 p.m. CEST, 3.24 percent above the Xetra close of October 13, 2026. The price-to-earnings ratio was 91.73, placing valuation alongside the day's strong move.

Sartorius schedules its conference call for the nine-month 2026 results on October 22, 2026 at 1:00 p.m. CEST. That date gives the market a near-term checkpoint after the latest price move.

Guidance sets the next benchmark

For fiscal 2026, Sartorius guides for sales revenue growth of 5 to 9 percent in constant currencies, including a contribution from the MATTEK acquisition and US tariff surcharges. The company also expects its underlying EBITDA margin to rise above 30 percent, compared with 29.7 percent in fiscal 2025, according to Sartorius.

The guidance range matters because the stock is already valued at a 91.73 price-to-earnings ratio. The combination of a double-digit valuation and a 5 to 9 percent sales outlook leaves the October 22 report as the next test of execution.

Stock remains below its yearly high

The Lang & Schwarz price was EUR 12.45 below the 52-week high of EUR 271.90 and EUR 60.95 above the 52-week low of EUR 198.50 on October 14, 2026. The current level is therefore 4.58 percent below the high and 30.63 percent above the low.

Goldman Sachs raised its Sartorius target from EUR 228.00 to EUR 244.00 and kept a Neutral rating on October 1, 2026, citing a stable recovery in bioprocessing, according to FinanzNachrichten. The target remains below the Lang & Schwarz price, while the scheduled results date offers a nearer valuation catalyst.

Comparison with peers

Sartorius: plus 3.24 percent, P/E 91.73, market capitalization EUR 18.0 billion.

Danaher (NYSE, USD): plus 0.09 percent, P/E 39.63, market capitalization USD 156.8 billion.

Thermo Fisher Scientific (NYSE, USD): plus 1.18 percent, P/E 36.10, market capitalization USD 248.0 billion.

Price and reporting date

Sartorius was trading at EUR 259.45 at Lang & Schwarz on October 14, 2026 at 5:05 p.m. CEST, up 3.24 percent versus the Xetra close of October 13, 2026 at EUR 251.30. The valuation and the October 22 reporting date frame the next market assessment without constituting an investment recommendation.

The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.